우리나라 폐동맥고혈압환자에 대한 Bosentan과 Iloprost의 비용-효용 분석

• 영문명: Cost-Utility Analysis of Bosentan Versus Iloprost in Korean Patients with Pulmonary Arterial Hypertension
• 발행기관: 대한약학회
• 저자명: 손현순(Hyun Soon Sohn) 이태진(Tae-Jin Lee)
• 간행물 정보: 『약학회지』제54권 제2호 (2010년), 126~133쪽, 전체 8쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2010.04.30

영문 초록

This study was conducted to analyze cost-utility of bosentan versus iloprost indicated for pulmonary arterial hypertension (PAH) in a Korean healthcare setting from a payer’s perspective. We constructed a Markov model to estimate total costs and outcomes for 1-year time horizon in a hypothetical cohort of 50-year-old patients with PAH. Base analysis showed that bosentan resulted in KW 5.5 billions saving and 18 quality-adjusted life year (QALY) gains per 100 patients compared to iloprost. Bosentan as a dominant strategy was found to be robust through various sensitivity analyses.

키워드

cost-effectiveness cost-utility pulmonary arterial hypertension bosentan iloprost